Trial Updates

Eptinezumab initiated during a migraine prolongs time to subsequent attacks 4:37
Eptinezumab initiated during a migraine prolongs time to subsequent attacks
Roger Cady • 15 Jun 2021
Patient-identified most bothersome symptom as a novel outcome measure in migraine prevention trials 2:41
Patient-identified most bothersome symptom as a novel outcome measure in migraine prevention trials
Roger Cady • 15 Jun 2021
RELIEF trial results: eptinezumab demonstrates efficacy when administered during a migraine attack 4:47
RELIEF trial results: eptinezumab demonstrates efficacy when administered during a migraine attack
Roger Cady • 15 Jun 2021
Work productivity improves in patients with RRMS treated with ocrelizumab 4:55
Work productivity improves in patients with RRMS treated with ocrelizumab
Giancarlo Comi • 21 Jun 2021
Why are B-cells such a valuable target in MS? 3:09
Why are B-cells such a valuable target in MS?
Giancarlo Comi • 21 Jun 2021
Apitegromab for the treatment of SMA 2:49
Apitegromab for the treatment of SMA
Gabriele Siciliano • 15 Jun 2021
Therapies in the pipeline for Huntington’s disease 1:54
Therapies in the pipeline for Huntington’s disease
Anne Rosser • 18 Jun 2021
Cell therapy in Huntington’s disease: where are we now? 2:58
Cell therapy in Huntington’s disease: where are we now?
Anne Rosser • 18 Jun 2021
Huntingtin-lowering strategies for Huntington’s disease 2:56
Huntingtin-lowering strategies for Huntington’s disease
Anne Rosser • 18 Jun 2021
Plasma exchange in the treatment landscape of AD 1:46
Plasma exchange in the treatment landscape of AD
Javier Olazarán • 18 Jun 2021
AMBAR study: plasma exchange plus albumin in mild/moderate Alzheimer’s disease 4:28
AMBAR study: plasma exchange plus albumin in mild/moderate Alzheimer’s disease
Javier Olazarán • 18 Jun 2021
Migraine symptom resolution occurs within an hour with eptinezumab administered during an attack 6:17
Migraine symptom resolution occurs within an hour with eptinezumab administered during an attack
Jessica Ailani • 21 Jun 2021
Total pain burden reduced by galcanezumab in treatment-resistant migraine 6:19
Total pain burden reduced by galcanezumab in treatment-resistant migraine
Jessica Ailani • 21 Jun 2021
CASTING: ocrelizumab safety profile in RRMS 2:16
CASTING: ocrelizumab safety profile in RRMS
Celia Oreja-Guevara • 20 Jun 2021
Promising clinical trials in CBI: ENVIS-ion study 1:06
Promising clinical trials in CBI: ENVIS-ion study
Thomas Meinel • 7 Jun 2021
Cenobamate efficacy occurs early during titration 1:37
Cenobamate efficacy occurs early during titration
Bernhard Steinhoff • 4 Jun 2021
The content of VJNeurology is intended for healthcare professionals